维奈托克联合阿扎胞苷治疗高危型骨髓增生异常综合征的临床分析

Clinical Analysis of Venetoclax Combined with Azacitidine in Hig-risk Myelodysplastic Syndrome

目的 探究维奈托克联合阿扎胞苷治疗高危型骨髓增生异常综合征的疗效及安全性。方法 选取齐齐哈尔医学院附属第二医院2019年6月—2022年6月收治的56例高危型骨髓增生异常综合征患者作为研究对象,采用简单随机抽样法将患者分为对照组(30例)和研究组(26例)。对照组采用阿扎胞苷化疗,研究组在对照组治疗基础上加用维奈托克治疗。比较两组疗效、不良反应及血清乳酸脱氢酶、β2微球蛋白、叶酸的水平。结果 研究组疗效总有效率高于对照组(P<0.05),两组不良反应的总发生率比较差异无统计学意义(P>0.05),治疗后研究组血清乳酸脱氢酶、β2微球蛋白、叶酸水平均低于对照组(P<0.05)。结论 维奈托克联合阿扎胞苷化疗方案可提高高危型骨髓增生异常综合征的治疗效果,且安全可靠。

Objective To investigate the efficacy and safety of Venetoclax combined with Azacitidine in the treatment of high-risk myelodysplastic syndrome.Methods A total of 56 patients with high-risk myelodysplastic syndrome were enrolled from June 2019 to June 2022 in the Second Affiliated Hospital of Qiqihar Medical University.The patients were divided into a control group(n=30)and a study group(n=26)by simple random sampling.The control group received Azacitidine chemotherapy.The study group received Venetoclax combined with Azacitidine chemotherapy.The efficacy,adverse reactions,lactate dehydrogenase,β2 microglobulin,and folic acid were compared between the two groups.Results The overall response rate in the study group was higher than that in the control group(P<0.05).The was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After treatment,the serum levels of lactate dehydrogenase,β2 microglobulin and folic acid in the study group were all lower than those in the control group(P<0.05).Conclusion Venetoclax combined with Azacitidine can improve the therapeutic effect and safety on high-risk myelodysplastic syndrome.